Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart

Diabetes

Volumn 51, Issue 4, 2002, Pages 1110-1117

  Sidell, Robert J ^a   Cole, Mark A ^a   Draper, Nicholas J ^a   Desrois, Martine ^a   Buckingham, Robin E ^b   Clarke, Kieran ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INSULIN RESISTANCE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; RISK MANAGEMENT;

EID: 0036224012     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.4.1110     Document Type: Article

References (49)

1. Obesity in the new millennium
2. Diabetes. The missing link with obesity?
3. Cardiovascular abnormalities associated with human and rodent obesity
4. Isolated hearts from obese rats show impaired function during hypoxia
5. Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats
6. Failure of insulin-regulated recruitment of the glucose transporter GLUT4 in cardiac muscle of obese zucker rats is associated with alterations of small-molecular-mass GTP-binding proteins
7. Dysregulation of glucose transport and transporters in perfused hearts of genetically obese (fa/fa) rats
8. Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4
9. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis
10. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved
11. Glucose flux rate regulates onset of ischemic contracture in globally underperfused rat hearts
12. Roles of PPARs in health and disease
13. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
14. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
15. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes
16. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
17. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
18. Troglitazone action is independent of adipose tissue
19. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
20. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats
21. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs
22. Lipotoxic heart disease in obese rats: Implications for human obesity
23. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
24. Rosiglitazone prevents ischemic injury in the obese Zucker rat heart
25. Free fatty acids, but not ketone bodies, protect diabetic rat hearts during low-flow ischemia
26. Is lactate-induced myocardial ischaemic injury mediated by decreased pH or increased intracellular lactate?
27. In vivo insulin signaling in the myocardium of streptozotocin-diabetic rats: Opposite effects of diabetes on insulin stimulation of glycogen synthase and c-Fos
28. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow
29. Comparative studies on fatty acid synthesis, glycogen metabolism, and gluconeogenesis by hepatocytes isolated from lean and obese Zucker rats
30. Endogenous glucose production, gluconeogenesis and liver glycogen concentration in obese non-diabetic patients
31. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: A quantitative study
32. Protons in ischemia: Where do they come from; where do they go to?
33. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats
34. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats
35. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects
36. Effects of wortmannin on insulin and ishemia-induced stimulation of GLUT4 translocation and FDG uptake in perfused rat hearts
37. Preconditioning enhanced glucose uptake is mediated by p38 MAP kinase not by phosphatidylinositol 3-kinase
38. Alpha-adrenergic stimulation mediates glucose uptake through phosphatidylinositol 3-kinase in rat heart
39. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of P13-kinase
40. Cellular and molecular regulation of cardiac glucose transport
41. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
42. Effects of free fatty acids on glucose transport and IRS-1 -associated phosphatidylinositol 3-kinase activity
43. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
44. Regulation of GLUT4 gene expression by arachidonic acid: Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2
45. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
46. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter
47. Acitvators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells
48. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice